SaferWorldbyDesign hat dies direkt geteilt
Empowering Breakthrough Therapies | Business Development Manager - 3D In Vitro Models at InSphero | Driving Innovation in Drug Discovery | Philly area biotech advocate | Community organizer @STEMPeers.org
When I joined InSphero just a few weeks ago, I didn’t realize how productive the team is in advancing original research. Now, as I’m enjoying my morning coffee (the scientist in me drinks from a modified beaker!), I couldn’t help but dive into the latest paper from InSphero’s liver safety group, published in Toxicological Sciences in collaboration with the US FDA. Here are the key takeaways (Link to the paper is in the comments): ➡️ 152 FDA-approved drugs were tested with our 3D liver microtissues to assess DILI risk—one of the top reasons for drug development failure. ➡️ Our model flagged 80% of withdrawn drugs due to liver toxicity and classified 89% of safe drugs. For liver-toxic drugs targeting the nervous system, it had a >90% success rate. ➡️ Our 384-well Akura™ Spheroid Microplates enable scalable, automated screening for large-scale hepatotoxicity assessment. ➡️ Complexity isn’t always better—fit-for-purpose complex in vitro models are key for the adoption of NAMs, ensuring biological relevance, faster results, and cost-efficiency. Proud to be part of a team pushing the industry forward! #LiverToxicity #3DCellCulture #Toxicology #DrugDevelopment #InVitroModels #NAMs #InSphero #PharmaInnovation #SafetyScience #Biotech InSphero Arumugham (Ragoo) RaghunathanBärbel UlmerChristine Schwenk Sue Grepper, PhD Bruno Filippi Maria Vittoria Colombo Monika Tu Lola Fäs Friederike Wenz Katarzyna Sanchez Natalia Zapiórkowska-Blumer Hajnalka Varga Karolina Kaczmarska